Table 5.

Panobinostat in published phase II clinical trials in solid tumors.

Disease	Regimen	No. pts.	PFS	Efficacy	Ref.
Refractory metastatic renal cell carcinoma.	Panobinostat: 45 mg orally twice a week	20		OR 0	[99]
Previously treated advanced pancreatic cancer	Panobinostat: 20 mg orally three times weekly +Bortezomib: 1.3 mg/m2 IV twice weekly, both during the first two weeks, followed by a 9-day rest period.		Median: 2.1 m.	OR 0	[100]

Abbreviations: m., months; MBC, metastatic breast cancer; No., number; OR, objective response; PFS, progression free survival; pts, patients; Ref., references.